SSelectStock

SANOFICONRSanofi Consumer Healthcare India Limited

Pharma · Drug Manufacturers - General · NSE · as of 2026-09-11 (delayed ~30 min in market hours)

Sanofi Consumer Healthcare India Limited operates as a fast-moving consumer healthcare company in India. The company offers products in the allergy, physical wellness, and pain care segments under Allegra, Combiflam, Avil, DePURA, Festal, and other brand names through distributors, wholesalers, government institutions and hospitals, pharmacy chains, and e-commerce platforms. The company was incorporated in 2023 and is based in Mumbai, India. Sanofi Consumer Healthcare India Limited operates as a subsidiary of Opella Healthcare Participations B.V.

4,023.40
1.62%
49Average

Mkt Cap
₹9,278 Cr
P/E
35.9
P/B
24.0
Div Yield
1.83%
52W High
₹5,275.81
52W Low
₹3,914.76

Price & Volume

Loading chart…

Key Ratios

Market Cap (₹ cr)9,277.80
P/E35.93
P/B24.04
PEG1.04
ROE %62.50
ROCE %72.70
Debt / Equity0.06
EPS111.98
Revenue Growth %32.80
Profit Growth %35.70
Dividend Yield %1.83
Promoter Holding %71.46
FII Holding %18.13
DII Holding %
Beta0.50

“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.

Active Pattern Signals

None of the 16 pattern scanners currently detects a setup on SANOFICONR — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.

HOLDConviction 51%

The picture

  • Revenue growth: 32.8% YoY
  • Profit growth: 35.7% YoY
  • ROE: 62.5%
  • Sector momentum: sector +6.2% (1m)
  • Volatility: 31% annualized
  • Beta: 0.50

Bull case

  • Revenue growth: 32.8% YoY
  • Profit growth: 35.7% YoY
  • ROE: 62.5%
  • Sector momentum: sector +6.2% (1m)

Bear case

  • RSI: 28
  • MACD: bearish
  • 1-month return: -10.0%
  • 1-month vs NIFTY: -5.9% relative

Key risks

  • Momentum is fading versus the broader market
  • RSI: 28
  • MACD: bearish

Algorithmic analysis for research only — not SEBI-registered investment advice.

Trade Plan

Entry (CMP)
₹4,023.40
Stop Loss
₹3,961.09
risk 1.5%
Target 1 (1.5R)
₹4,116.87
+2.3%
Target 2 (3R)
₹4,210.33
+4.6%
Support (20d)
₹4,001.10
Resistance (52w)
₹5,275.81
Risk : Reward
1 : 1.5 → 1 : 3
risking ₹62.31/share
ATR (volatility)
₹105.29
avg daily range

Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹105.29). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.

Score Breakdown

Fundamental98
Technical18
Momentum23
Risk (safety)60

Peers — Pharma

CORONA 1.60%
87
GRANULES 1.12%
81
LAURUSLABS 1.23%
79
KPL 3.75%
79
DIVISLAB 1.23%
79
CAPLIPOINT 1.45%
78